INOVIO, the Doylestown-based pharmaceutical company, has completed the first phase of its clinical trial for a COVID-19 vaccine. All 40 healthy volunteers in the trial have now received their first dose, INOVIO says.
Interim immune responses and safety results are expected in late June, the company says. The trial’s volunteers are enrolled at sites at the University of Pennsylvania in Philadelphia and a clinic in Kansas City, Missouri.
The volunteers will receive two doses of INO-4800 in total, four weeks apart. INOVIO is on track to deliver a million doses of a COVID-19 vaccine by year’s end. The company previously created a successful vaccine for a related coronavirus that causes Middle East Respiratory Syndrome, or MERS.
